Physician profile
Barry L Smith
NPI 1770568073
$8,764.90
in general payments reported to CMS, 2019-2025
19 companies · $3,030 in 2025
The $3,030 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2021: $249 · 2022: $379 · 2023: $4,066 · 2024: $580 · 2025: $3,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,425 · Food and Beverage: $3,193 · Travel and Lodging: $57.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,425.00 |
| Food and Beverage | $3,192.54 |
| Travel and Lodging | $57.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,009.48 | 2023 | Ilumya |
| Galderma Laboratories, L.P. | $2,011.91 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $1,073.44 | 2022-2025 | Sotyktu |
| Incyte Corporation | $712.39 | 2023-2025 | Opzelura |
| Amgen INC. | $357.41 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $320.52 | 2022-2025 | Rinvoq |
| Celgene Corporation | $304.73 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $266.50 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $181.15 | 2024-2025 | Adbry, Anzupgo |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Arcutis Biotherapeutics, INC. | $86.95 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $75.74 | 2025 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Lilly USA, LLC | $41.12 | 2024-2025 | Olumiant, Ebglyss, Taltz |
| Janssen Biotech, INC. | $30.70 | 2025 | Tremfya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $29.25 | 2025 | Bimzelx |
| Genzyme Corporation | $28.21 | 2025 | |
| Genentech USA, INC. | $22.57 | 2025 | Xolair |
| Botanix Sb INC | $15.83 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.